利妥昔单抗联合化疗治疗难治复发弥漫大B细胞淋巴瘤临床观察

李小妮

（宝鸡市中心医院血液风湿病科，陕西 宝鸡，721008）

浏览次数：191次 下载次数：459次

摘要：

目的 为有效控制难治复发性弥漫大B细胞淋巴瘤疾病，探究利妥昔单抗联合化疗用于该疾病治疗的可行性、有效性。方法 选取我院诊断为难治复发性弥漫大B细胞淋巴瘤的80例患者，随机分为单一组和治疗组，每组均为40 例。其中单一组仅使用ECHOP方案控制疾病发展，治疗组使用R-DHAP方案联合利妥昔单抗，对两组患者的临床疗效和不良反应情况进行统计比较。结果 单一组临床有效率（27.5%）低于治疗组（62.5%），差异有统计学意义（P<0.05）；治疗组肝功能损害、骨髓抑 制、胃肠道反应、肾功能损害发生率依次为5.0%、22.5%、25.0%、2.5%，单一组依次为15.0%、40.0%、50.0%、17.5%，单一组均高于治疗组，差异有统计学意义（P<0.05）。结论 临床对难治复发弥漫大B 细胞淋巴瘤患者治疗时，选择R-DHAP方案化疗，能有效控制瘤体发展，且不良反应少、用药安全性高。

关键词：利妥昔单抗；淋巴瘤；难治复发弥漫大B 细胞淋巴瘤

中图分类号：R733.1文献标志码：A文章编号：2096-1413(2016)25-0054-02

Clinical observation of rituximab injection and chemotherapy in the treatment of relapsed refractory diffuse large B cell lymphoma
LI Xiao-ni
(Department of Blood Rheumatism, Baoji Central Hospital, Baoji 721008, China)

ABSTRACT: Objective To effectively control the relapsed refractory diffuse large B cell lymphoma and explore the feasibility and effectiveness of rituximab injection and chemotherapy. Methods Eighty patients with relapsed refractory diffuse large B cell lymphoma confirmed in our hospital were selected and randomly divided into single group and treatment group, with 40 cases in each group. The single group just took ECHOP therapy to control the disease development, while the treatment group adopted R-DHAP therapy and rituximab injection. The clinical effect and adverse event were counted. Results The clinical effective rate of the single group (27.5%) was lower than that of treatment group (62.5%), the difference was statistically significant (P<0.05);the incidence rate of liver function impairment, bone marrow suppression, gastrointestinal reaction and renal dysfunction in the treatment group were 5.0%, 22.5%, 25.0% and 2.5%, while the rate in the single group were 15.0%, 40.0%, 50.0% and 17.5%, the difference was statistically significant (P<0.05). Conclusion For patients with relapsed refractory diffuse large B cell lymphoma, the R-DHAP therapy can effectively control the tumor development, reduce the adverse event and improve the clinical safety.
KEYWORDS: rituximab; lymphoma; relapsed refractory diffuse large B cell lymphoma

参考文献:
[1] 郭丽堃,黎民君,罗华山,等.利妥昔单抗联合CHOP方案治疗B 细胞型非霍奇金淋巴瘤的疗效评价[J].肿瘤药学,2012,2(2):120-122.
[2] 黄泉,季美华,张瑾,等.利妥昔单抗联合CHOP方案治疗B 细胞非霍奇金淋巴瘤疗效观察[J].海南医学,2013,24(19):2824-2827.
[3] 田垚垚,王树叶,李晓霞,等.减量CHOP方案联合利妥昔单抗对老年B细胞非霍奇金淋巴瘤的疗效和安全性[J].中华内科杂志,2012,51(12):994-996.
[4] 徐晓燕.利妥昔单抗联合CHOP治疗B细胞性非霍奇金淋巴瘤的治疗体会[J].中国实用医药,2012,7(19):162-163.
[5] 王谷云,姚红霞,林丽娥,等.R-CHOP方案治疗侵袭性B 细胞淋巴瘤15例[J].中国老年学杂志,2013,33(2):413-414.